Core Viewpoint - Tonghua Golden Horse announced the approval of its 2025 semi-annual report and summary by the 10th meeting of the 11th Board of Directors [2] Group 1 - The company held its 10th meeting of the 11th Board of Directors on August 20 [2] - The meeting resulted in the approval of the company's 2025 semi-annual report and its summary [2]

Core Viewpoint - Tonghua Golden Horse (000766) reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating a positive trend in financial performance despite a challenging market environment [1][2]. Financial Performance - The company achieved an operating income of 650 million yuan, a year-on-year increase of 0.12% [1]. - The net profit attributable to shareholders was 16.804 million yuan, reflecting a year-on-year growth of 34.77% [1]. - The net profit after deducting non-recurring gains and losses was 14.4073 million yuan, showing a substantial increase of 125.07% year-on-year [1]. - Basic earnings per share were reported at 0.02 yuan [1]. Business Overview - Tonghua Golden Horse is primarily engaged in the research, production, and sales of pharmaceutical products, with a diverse product range covering oncology, microbiology, cardiovascular, detoxification, digestive, musculoskeletal, gynecological, and neurological systems [1]. - The company operates through various business units, including its headquarters, Shengtai Biological, Yongkang Pharmaceutical, and Yuanshou Biological [1]. Research and Development - The company focuses on enhancing professional skills and quality research levels, aiming to improve its technological innovation capabilities and market influence [2]. - Tonghua Golden Horse is developing a self-researched national class 1.1 new drug, Succinic Dihydrogenated Aminoacridine Tablets, which has received a notice of acceptance for its market application from the National Medical Products Administration [2][3]. - The drug is intended for the treatment of mild to moderate Alzheimer's disease and has undergone various clinical trial phases since 2007 [3]. Regulatory and Market Position - The company is actively working on the registration and market launch of Succinic Dihydrogenated Aminoacridine Tablets, adhering to relevant laws and guidelines [2][3]. - The drug's approval process is currently ongoing, with the company maintaining communication with the Center for Drug Evaluation (CDE) to address any inquiries during the review process [3].

Group 1 - Weicai Technology achieved a net profit of 101 million yuan in the first half of 2025, a year-on-year increase of 831.03% [1] - The company reported an operating income of 634 million yuan, up 47.53% year-on-year, with a basic earnings per share of 0.68 yuan [1] - Weicai Technology specializes in wafer testing, chip finished product testing, and related integrated circuit testing services [1] Group 2 - Changhua Group received a project development notification from a domestic automotive company, with an expected total sales amount of approximately 190 million yuan over an 8-year lifecycle [2] - The project is set to begin mass production in the third quarter of 2026 [2] - Changhua Group focuses on the research, production, and sales of automotive metal components [2][3] Group 3 - Junhe Co. reported a net profit of 30.99 million yuan in the first half of 2025, a year-on-year decrease of 19.53% [3] - The company achieved an operating income of 578 million yuan, up 5.53% year-on-year, with a basic earnings per share of 0.08 yuan [3][4] - Junhe Co. specializes in the research, design, manufacturing, and sales of household water pumps and their accessories [4] Group 4 - Tonghua Jinma reported a net profit of 16.80 million yuan in the first half of 2025, a year-on-year increase of 34.77% [5] - The company achieved an operating income of 650 million yuan, a slight increase of 0.12% year-on-year, with a basic earnings per share of 0.0174 yuan [5] - Tonghua Jinma focuses on the research, production, and sales of pharmaceutical products [5][6] Group 5 - Xing Shuai reported a net profit of 122 million yuan in the first half of 2025, a year-on-year increase of 31.79% [8] - The company achieved an operating income of 1.132 billion yuan, up 8.59% year-on-year, with a basic earnings per share of 0.37 yuan [8] - Xing Shuai specializes in the research, production, and sales of various types of refrigeration compressor thermal protectors, starters, and temperature controllers [8] Group 6 - Ice Wheel Environment reported a net profit of 266 million yuan in the first half of 2025, a year-on-year decrease of 19.71% [9] - The company achieved an operating income of 3.118 billion yuan, down 6.92% year-on-year, with a basic earnings per share of 0.27 yuan [9] - Ice Wheel Environment focuses on the research, design, and sales of artificial environment control technology and energy comprehensive utilization technology [9][10] Group 7 - Jiangsu Huachen reported a net profit of 47.27 million yuan in the first half of 2025, a year-on-year increase of 18.37% [18] - The company achieved an operating income of 938 million yuan, up 40.46% year-on-year, with a basic earnings per share of 0.2901 yuan [18] - Jiangsu Huachen specializes in the research, production, and sales of energy-saving transformers and smart electrical equipment [18] Group 8 - Hanma Technology reported a net profit of 27.73 million yuan in the first half of 2025, reversing from a loss of 153 million yuan in the same period last year [18] - The company achieved an operating income of 2.847 billion yuan, a year-on-year increase of 50.03% [18] - Hanma Technology focuses on the production, research, and sales of heavy trucks, special vehicles, and automotive components [18] Group 9 - Tianyue Advanced announced the listing of its H-shares on the Hong Kong Stock Exchange, raising approximately 1.938 billion HKD [19] - The global offering consisted of 47.7457 million shares, with a price of 42.80 HKD per share [19] - Tianyue Advanced specializes in the research, production, and sales of silicon carbide semiconductor materials [19][20] Group 10 - Kesi Technology signed a sales framework contract worth up to 401 million yuan with Beijing Tianyuan Innovation Technology Co., Ltd. [21] - The contract is valid for two years and involves a comprehensive information integration service project [21] - Kesi Technology focuses on the research, development, manufacturing, and sales of electronic information equipment [21][22]

Group 1: Fund Companies and ETFs - 14 fund companies have submitted applications for the second batch of Sci-Tech Innovation Bond ETFs, with 8 companies applying for products listed on the Shanghai Stock Exchange and 6 on the Shenzhen Stock Exchange [1] - The second batch of ETFs will track three indices: the CSI AAA Technology Innovation Corporate Bond Index, the SSE AAA Technology Innovation Corporate Bond Index, and the SZSE AAA Technology Innovation Corporate Bond Index [1] - Multiple banks, including Industrial Bank, China Merchants Bank, and CITIC Bank, are involved in the custody of these ETFs, marking a shift from the previous batch where only Industrial Bank was the custodian [1] Group 2: Banking Sector - Several village banks in regions like Zhejiang, Guizhou, and Jilin have announced reductions in deposit interest rates, with cuts ranging from 10 to 20 basis points [1] - This trend is primarily observed among small and medium-sized banks, which are adjusting deposit rates to stabilize net interest margins amid declining trends [1] - The ongoing reduction in deposit rates is expected to continue, prompting smaller banks to rethink their reliance on high-interest deposits and develop differentiated products and services [1] Group 3: Technology and AI Market - IDC reports that the market size for large model development platforms in China is expected to reach 1.69 billion yuan in 2024, driven by applications in productivity enhancement and marketing [2] - The top six companies in this market include Baidu Smart Cloud, Alibaba Cloud, SenseTime, Zhipu AI, Telecom AI, and Xiyu Technology [2] Group 4: Automotive and Electronics - Omdia predicts that global shipments of foldable OLED screens will reach 124.6 million units by 2032, significantly higher than the estimated 23.1 million units in 2024 [2] - The growth in foldable smartphone shipments is expected to increase fivefold over the next eight years, driven by continuous innovation in new models [2] Group 5: Pharmaceutical and Animal Health - The first prescription drug for stress relief in cats, named "Miao Neng," has been launched in China, priced at 69.8 yuan for a three-pack and 124.8 yuan for a six-pack [3] - This product is noted for its rapid action, high targeting, and superior safety compared to existing alternatives in the market [3] Group 6: Corporate Developments - American Bank has reportedly hired Barclays' Sandeep Tharian to lead its Asia-Pacific credit sales business, indicating a strategic move to strengthen its presence in the region [4] - Okai Airlines and other companies have been executed for over 620 million yuan due to financial loan disputes, highlighting ongoing financial challenges within the aviation sector [4] Group 7: Market Performance - The ChiNext 50 Index surged over 3%, reaching a new high for the year, with significant trading volume across the Shanghai and Shenzhen markets [11] - Chip stocks experienced a notable rally, with companies like Cambricon reaching historical highs, while consumer stocks also showed signs of recovery [11]

格隆汇8月20日丨通化金马(000766.SZ)公布2025年半年度报告，上半年公司实现营业收入6.5亿元，同比 增长0.12%；归属于上市公司股东的净利润1680.4万元，同比增长34.77%；归属于上市公司股东的扣除 非经常性损益的净利润1440.73万元，同比增长125.07%；基本每股收益0.0174元。 ...

人民财讯8月20日电，通化金马（000766）8月20日晚间披露2025年半年报，公司上半年实现营业收入 6.5亿元，同比增长0.12%；归母净利润1680.4万元，同比增长34.77%；基本每股收益0.0174元。 ...

Core Viewpoint - Tonghua Golden Horse (000766.SZ) reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating positive financial performance despite a modest growth in sales [1] Financial Performance - The company achieved an operating income of 650 million yuan, representing a year-on-year growth of 0.12% [1] - The net profit attributable to shareholders reached 16.804 million yuan, showing a year-on-year increase of 34.77% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 14.4073 million yuan, reflecting a substantial year-on-year growth of 125.07% [1] - Basic earnings per share were reported at 0.0174 yuan [1]

单位：通化金马药业集团股份有限公司 单位：人民币元 非经营性资金占用 资金占用方名称 占用方与上市公 司的关联关系 上市公司核算 的会计科目 2025年期初占用资金 余额 2025年半年度占用累计发 生金额（不含利息） 2025年半年度占用资 金的利息 2025年半年度偿还累 计发生金额 2025年半年度期末占 用资金余额 占用形成原因 占用性质 - - 小计 - - - - - 前控股股东、实际控 制人及其附属企业 - 小计 - - - - - 其他关联方及其附 属企业 - 小计 - - - - - 总计 - - - - - 其它关联资金往来 资金往来方名称 往来方与上市公 司的关联关系 上市公司核算 的会计科目 2025年期初往来资金 余额 2025年半年度往来累计发 生金额（不含利息） 2025年半年度往来资 金的利息 2025年半年度偿还累 计发生金额 2025年半年度期末往 来资金余额 往来形成原因 往来性质 控股股东、实际控制人及其附属企 业 苏州恒义天成投资管理中心（有限合 伙） 孙公司 其他应收款 157,343,751.40 157,343,751.40 往来借款 非经营性往来 通化神源药业 ...

通化金马药业集团股份有限公司 2025 年半年度财务报告 通化金马药业集团股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：通化金马药业集团股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 343,686,786.24 | 274,177,490.80 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 1,068,300.42 | 1,088,562.40 | | 衍生金融资产 | | | | 应收票据 | | | | 应收账款 | 513,987,637.44 | 499,551,966.08 | | 应收款项融资 | 26,732,881.25 | 26,715,894.78 | | 预付款项 | 9,531,344.58 | 10,568,328.57 | | 应收保费 | | | | 应收分保账款 ...

证券代码：000766 证券简称：通化金马 公告编号：2025-30 通化金马药业集团股份有限公司 3.会议应到董事 9 人，实到董事 9 人。 4.会议由董事长张玉富先生主持。部分高管人员列席了本次会议。 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定。 二、董事会会议审议情况 审议并通过公司 2025 年半年度报告及其摘要 公司 2025 年半年度报告及其摘要同日披露于巨潮资讯网。 第十一届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1.通化金马药业集团股份有限公司第十一届董事会第十次会议通知于 2025 年 8 月 11 日以微信和电子邮件形式送达全体董事。 2.2025 年 8 月 20 日上午 9 时 30 分在公司七楼会议室以现场和通讯方式召 开。 本议案已经董事会审计委员会全票审议通过。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 三、备查文件 经与会董事签字并加盖董事会印章的董事会决议。 通化金马药业集团股份有限公司董事会 2025 年 8 ...